Neuroendocrine carcinoma (NEC) is uncommon in the head and neck and rare in the salivary glands. In the latter location, it may manifest as pain or a palpable mass. These tumors can be quite aggressive, with a tendency toward recurrence and regional and distant metastasis. Because of the limited number of reported cases in the literature, no reliable treatment has been established. We describe the case of a 79-year-old man who presented with a persistent submandibular mass that was suspicious for a malignancy on imaging. Following surgical resection and histopathologic analysis, a diagnosis of poorly differentiated small-cell NEC was made. The patient was further treated with postoperative chemotherapy, and he exhibited no evidence of recurrence or metastasis on follow-up.
Introduction
Neuroendocrine tumors include both neuroendocrine carcinoma (NEC), which is of epithelial origin, and nonepithelial neural tumors, such as olfactory neuroblastoma and paraganglioma. The paraganglion system functions in fetal life to serve the role that the adrenal medulla will largely assume after it develops-that is, to secrete and store catecholamines via chromaffin cells, which are neuroectodermally derived.
Several nomenclature systems [1] [2] [3] have been proposed throughout the years to classify the different the types of NEC, including carcinoid tumors, atypical carcinoids, small-cell NECs, and large-cell NECs:
• Carcinoid tumors, which are also known as typical carcinoids, are well-differentiated, grade I NECs.
• Atypical carcinoids are moderately differentiated, and they are classified as grade II NECs.
• Small-cell NECs are poorly differentiated, grade III tumors. Some authors continue to refer to these tumors incorrectly as small-cell undifferentiated carcinomas. However, these tumors are not "undifferentiated. " Rather, they exhibit a definite neuroendocrine phenotype on immunohistochemistry and electron microscopy.
• Large-cell NECs are also poorly differentiated tumors.
The term small-cell as a description of a grade III NEC is used because the cancer cells are smaller than those of a typical adenocarcinoma or squamous cell carcinoma. Even so, these cells are about three times larger than a mature lymphocyte.
There is some controversy over the cell of origin of these tumors. Some authors have suggested that these tumors can also differentiate from ductal elements and exhibit myoepithelial differentiation as well as neuroendocrine features. 4 However, because nearly all progenitors of epithelial cells have the capacity for neuroendocrine differentiation and are commonly found among glandular elements, the debate may not be easily settled. 3 In this article, we describe a rare case of a poorly differentiated small-cell NEC of the submandibular gland.
Case report
A 79-year-old man was referred to our institution's head and neck oncology clinic with a 3-month history of a mass in the left submandibular area. He had been treated Poorly differentiated small-cell neuroendocrine carcinoma of the submandibular gland: a case rePort at another institution with a course of antibiotic therapy, but the status of the mass had not changed. Fine-needle aspiration biopsy (FNAB) was then performed, and it showed a neoplasm with epithelial features. Computed tomography (CT) of the chest was negative. The patient's medical history included coronary artery disease and sleep apnea. He had never used tobacco but did have a history of exposure to second-hand smoke.
Physical examination at our clinic revealed a firm, mobile, 2 × 3-cm mass in the left submandibular area. No cervical or facial lymphadenopathy was palpable, no intraoral lesions were seen, and the facial nerve was intact. Positron-emission tomography (PET)/CT detected a hypermetabolic lymph node anteroinferior to the left submandibular gland with a peak standardized uptake value of 11.3 (figure 1). The left submandibular gland was also identified as a distinct structure on CT. No abnormal uptake was noted elsewhere in the body. The patient was taken to the operating room for surgical excision of the left submandibular gland and submandibular contents. He tolerated the procedure well.
A review of the patient's initial FNAB results revealed a focal expression of chromogranin, weak focal cytoplasmic staining with a cytokeratin cocktail, and equivocal reactions with the myoepithelial markers calponin and p63. The tumor was thus differentiated from a neurally derived neuroendocrine tumor, which would have been negative for cytokeratin. The Ki-67 stain showed an elevated cell proliferation index of 30%, which was consistent with a poorly differentiated NEC. Histopathology of the resected gland revealed solid sheets of small round blue cells with indistinct nucleoli and focal areas of necrosis consistent with a poorly differentiated small-cell NEC (figure 2).
Postoperatively, the patient underwent six cycles of carboplatin and etoposide chemotherapy, which he tolerated well. He did not receive any radiation therapy. During more than 24 months of postoperative followup, the patient exhibited no evidence of recurrence or metastasis.
Discussion
Since the head and neck is an uncommon site for an NEC, information on prognosis and treatment derives mainly from small case series. Within the head and neck, the most common site is the larynx; other reported locations include the salivary glands, nasal cavity, paranasal sinuses, trachea and, in very rare cases, the oral cavity, including the uvula. 5 NECs of the salivary glands tend to be of the poorly differentiated small-cell type; most of these (>80%) have occurred in the parotid gland. 3 Poorly differentiated NEC of the salivary glands represents only 1 to 3% of all salivary malignancies. 3 The location of our patient's tumor in the submandibular gland is quite rare, as only 15 such cases have been previously reported in the English-language literature. [6] [7] [8] [9] [10] Preoperatively, some NECs are difficult to differentiate from a paraganglioma because of their vascularity and difficulty with biopsy as a result of their proximity to neurovascular structures in the neck. Once a biopsy has been obtained, immunohistochemical staining is important because it is independently diagnostic in 30 to 40% of cases. 11 The differences in the management strategy and prognosis between a paraganglioma and an NEC are stark, which makes this differentiation crucial.
In general, immunohistology of an NEC shows diffuse cytoplasmic staining with CD56, chromogranin, and synaptophysin ( figure 3 ). Unlike the epithelially derived NECs, the neurally derived paragangliomas do not stain with cytokeratins. Furthermore, NEC exhibits a specific dot-like staining pattern with pan-cytokeratin markers. Negative staining with thyroid transcription factor 1 supports a salivary gland site rather than a lung primary. 9 In view of the high mitotic rate seen in small-cell NEC, individual cell necrosis and small pools of necrosis are common features on light microscopy.
Because small-cell NEC is a malignant small round blue cell tumor of the head and neck, its differential diagnosis must include lymphoma, Ewing sarcoma, melanoma, rhabdomyosarcoma, and neuroblastoma (including olfactory neuroblastoma and esthesioneuroblastoma). With the exception of the neuroblastomas, these other tumors can be differentiated from small-cell NEC by their negative results on chromogranin and synaptophysin staining. Like paragangliomas, neuroblastomas can also be distinguished by their negative cytokeratin stains. 9 Symptoms generally depend on the specific tumor site. Dysphagia, a globus sensation, and respiratory distress can occur with laryngeal lesions. Pain or a palpable mass suggests a diagnosis of salivary gland involvement. Facial nerve palsy is a more ominous sign that typically identifies a malignant rather than benign disease. The age at presentation is typically beyond 50 years, and there seems to be a predilection for men. 3 Tobacco use is common among affected patients, but studies have not been large enough to prove that it is a causative factor. 3 Because of the small number of reported cases in the literature, it is difficult to characterize the typical stage at presentation; some reports have shown nearly all patients presenting at late stages, whereas others have included largely T1 and N0 lesions. [6] [7] [8] [9] In general, these tumors appear to be locally aggressive, and they have a propensity for recurrence and regional and distant metastasis. For tumors of the salivary glands, spread occurs via the hematogenous route. 3, 12 At our institution, the workup includes PET/CT and FNAB; however, while both may be helpful, neither is definitive. Chest imaging is crucial in order to rule out a lung primary.
Little consensus exists on the treatment of these tumors-again, because most of the literature contains only small case series or larger groups of dissimilar tumors. Some studies have suggested that the more advanced NECs, such as the poorly differentiated small-cell subtype, may be best treated with radiation and chemotherapy if the diagnosis is known prior to surgery. 13 In the absence of specific treatment guidelines, our institution's practice has been to consider a combination of local treatment (surgery or radiation) and systemic chemotherapy. However, others have pointed out that moderately and poorly differentiated NECs of the head and neck tend to be resistant to radiation and chemotherapy. 14 The treatment trend for localized salivary gland NEC, based on the limited amount of evidence in the literature, seems to be toward surgical resection (with lymphadenectomy for clinically obvious disease) with or without postoperative chemotherapy or radiation therapy. 3 Appropriate chemotherapeutic regimens have not been clearly delineated.
Survival rates for patients with a head/neck NEC vary somewhat according to subsite, but overall it is poor. Five-year survival for patients with a poorly differentiated tumor is 14%, while patients with a well-differentiated NEC have a 5-year survival rate of 34%. 14 Salivary gland NEC carries a slightly better overall prognosis; the 5-year survival rate is 46% overall, but only 30% for patients with a poorly differentiated small-cell NEC. [15] [16] [17] As poor as these rates are, a salivary gland subsite still carries a better prognosis than does a primary tumor of the lung, which is associated with a 5-year survival of about 5%. 9 As is the case with other head and neck primary cancers, patients with an NEC require close surveillance, including thorough physical examinations. CT of the neck, chest, and abdomen should be performed to monitor for recurrence and regional and distant metastasis. Recurrences of NEC have been reported as long as 5 years after the initial diagnosis, making long-term follow-up crucial, as well. 
